About Immutrin
Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-A
Global Headquarters
Cambridge, United Kingdom
Team Size
1-10
Tracked Since
Sep 29, 2026
Web & Domain Identity
Official Website
immutrin.com
Domain Registered Date
Sep 20, 2019
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $86,450,000 · Series-A
fundraisingfox.com
- Milestone
Website domain registered
immutrin.com
Investors & Backers
Cambridge Enterprise Ventures
Cambridge Innovation Capital
F-Prime Capital
Frazier Life Sciences
Parkwalk Advisors
Qiming Venture Partners
SR One
Funding History
Series-A
· Mar 26, 2026
$86,450,000 fundraisingfox.com
Founders & Leadership
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026